Copyright © 2015-2025 Durastab All rights reserved
Guangdong ICP No. 2022015551-1
Newsletter
By submitting this form,you consent to receive marketing updates from Durastab.
About Us
Durastab Medtec LTD has always adhered to the mission of "making diagnostic reagents more stable and more accurate" since its establishment, and is committed to providing excellent ready-to-use reagent solutions to global advanced medical diagnostic companies.
To date, Durastab has successfully provided products to over 600 companies and research teams at thousands of universities and scientific research institutions worldwide, among which are more than 50 listed IVD companies.
About UsContact Info
- B1501, Meixun Science Park, No.19, Jinxiu Zhonglu , Pingshan, Shenzhen
- +86-0755-32813268
- info@durastab.com
Flagship Product: Safer, More Stable, and More Versatile – ProCide 300 Preservative!
Newly Upgraded 3rd-Gen TMB Substrate: Enhanced Stability with Multiple Freeze-Thaw Tolerance!
New Product Launch – Bovine Serum Albumin (BSA) for Clinical Biochemistry, Immunoassays, and Molecular Detection!
Flagship Product: Safer, More Stable, and More Versatile – ProCide™ 300 Preservative!
Newly Upgraded 3rd-Gen TMB Substrate: Enhanced Stability with Multiple Freeze-Thaw Tolerance!
New Product Launch – Bovine Serum Albumin (BSA) for Clinical Biochemistry, Immunoassays, and Molecular Detection!
Signaling Systems and
Immunoassay Solutions Provider
Search
SearchBlocker
Active/ Passive Blockers
$0
Durastab's Blocker reagents are widely applicable in the R&D and industrial production of IVD kits. Customers can evaluate corresponding reagent series based on their specific assay systems to screen for the most effective component. The products are suitable for use in most IVD projects employing sandwich antigen detection, competitive, or IgM capture methods, such as in Cardiac Markers, Tumor Markers, Inflammatory Markers, Infectious Diseases, Thyroid Function, and Renal Function testing.
Blocker
Durastab's Blocker reagents effectively reduce false-positive or false-negative results caused by interferents in immunoassays. In immunoassay experiments, test results are susceptible to interference from endogenous antibodies or other immunoglobulin-binding substances present in samples. These interferents are collectively known as immunoassay interferents, and assay formats particularly vulnerable to interference primarily include sandwich, competitive, and IgM capture assays. Currently known major interferents include Heterophile Antibodies (HA), Rheumatoid Factors (RF), and Human Anti-Animal Antibodies (HAAA), among others.
Durastab's Blocker reagents are widely applicable in the R&D and industrial production of IVD kits. Customers can evaluate corresponding reagent series based on their specific assay systems to screen for the most effective component. The products are suitable for use in most IVD projects employing sandwich antigen detection, competitive, or IgM capture methods, such as in Cardiac Markers, Tumor Markers, Inflammatory Markers, Infectious Diseases, Thyroid Function, and Renal Function testing.
Active Blockers: This category of reagents exhibits high affinity for interfering antibodies. By actively binding to the interfering antibodies, they employ steric hindrance to block the interaction between the interfering antibodies and the detection or capture antibodies.
Passive Blockers: Typically consisting of animal serum or IgG, these reagents are added at high concentrations. They function by providing an excess of alternative binding sites, causing the interfering antibodies to preferentially bind to the blocker instead of the detection or capture antibodies, thereby reducing interference.
| Art no. | Type | Reaction System | Methodology | Application | Instructions |
|---|---|---|---|---|---|
| HBR-001 | Active & Passive | Mouse | Immunoassay | CLIA/ ELISA: Enzyme Conjugate: @ 5-100 μg/mL LFIA: Sample pad treatment: @ 0.2-0.4 mg/mL | |
| HBR-007 | Active & Passive | Mouse | Immunoassay | ||
| HBR-035 | Active & Passive | Mouse | CLIA, LFIA | CLIA: Enzyme Conjugate: @ 5-100 μg/mL LFIA: Sample pad treatment: @ 0.2-0.4 mg/mL | |
| HBR-041 | Active & Passive | Mouse | CLIA, LFIA | ||
| HBR-045 | Active & Passive | Mouse | CLIA, LFIA | ||
| HBR-064 | Active & Passive | Mouse | CLIA, LFIA | ||
| HBR-072 | Active & Passive | Mouse | CLIA, LFIA | ||
| HBR-157 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | CLIA: Enzyme Conjugate: @ 5-100 μg/mL LFIA: Sample pad treatment: @ 0.2-0.4 mg/mL Clinical chemistry: R1 reagent: @ 0.5-1.0 % (v/v) | |
| HBR-162 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | ||
| HBR-194 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | ||
| HBR-208 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | ||
| HBR-238 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | ||
| HBR-253 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | ||
| HBR-316 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | ||
| HBR-339 | Active & Passive | Mouse, Rabbit | CLIA, LFIA, Clinical chemistry | ||
| HBR-361 | Active & Passive | Mouse, Goat, Rabbi | CLIA, LFIA, Clinical chemistry | ||
| HBR-400 | Passive | Mouse | CLIA | CLIA: Enzyme Conjugate: @ 5-100 μg/mL | |
| HBR-401 | Passive | Mouse | CLIA | ||
| HBR-402 | Active & Passive | Mouse | Immunoassay | CLIA: Enzyme Conjugate: @ 5-100 μg/mL LFIA: Sample pad treatment: @ 0.2-0.4 mg/mL | |
| HBR-403 | Active & Passive | Mouse | Immunoassay |
Your All-Around Partner
- 360°
Committed to providing excellent ready-to-use reagent solutions to global advanced medical diagnostic companies.
Send Request